Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
ESMO Open
|
December 9, 2023
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre
M Mosteiro, D Azuara, S Villatoro, et al.
Drug Design and Discovery
|
May 12, 2000
New antiherpetic 1,3-phenylene derivatives, inhibitors of the interaction of the HSV-1 origin binding protein (OBP) with DNA
M Font, C Sanmartín, M L Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
A Martinez-Marti, E Felip, J Matito, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat, A Curioni-Fontecedro, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
E Felip, S Popat, U Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 19, 2020
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
J Remon, E Nadal, M Dómine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
E Pros, M Saigi, D Alameda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
ESMO Open
|
December 9, 2023
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre
M Mosteiro, D Azuara, S Villatoro, et al.
Drug Design and Discovery
|
May 12, 2000
New antiherpetic 1,3-phenylene derivatives, inhibitors of the interaction of the HSV-1 origin binding protein (OBP) with DNA
M Font, C Sanmartín, M L Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
A Martinez-Marti, E Felip, J Matito, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat, A Curioni-Fontecedro, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
E Felip, S Popat, U Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 19, 2020
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
J Remon, E Nadal, M Dómine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
E Pros, M Saigi, D Alameda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 7